SCHEMBL10129313

SCHEMBL10129313

COC(=O)Cc1ccc(-c2c3ccccc3c(-c3ccc(CC(=O)OC)cc3)c3cc(N(c4ccccc4)c4ccc5c(c4)c4ccccc4n5-c4ccccc4)ccc23)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.46
MAPT P10636 3/20 0.46
TSHR P16473 2/20 0.46
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
KDM4E B2RXH2 4/20 0.36
HSD17B10 Q99714 2/20 0.36
PLA2G2A P14555 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
PKM P14618 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
PTGER4 P35408 1/20 0.35
TSPO P30536 2/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10129760 0.96 HPGD (0.47) HPGDMAPTTSHRRXRARXRB
SCHEMBL10129307 0.90 HPGD (0.40) HPGDMAPTTSHRRXRARXRB
SCHEMBL10129332 0.88 HPGD (0.45) HPGDMAPTTSHRRXRARXRB
SCHEMBL10112492 0.86 KDM4E (0.42) HPGDMAPTKDM4EHSD17B10CYP1A2
SCHEMBL13615642 0.84 L3MBTL1 (0.47) HPGDMAPTKDM4EHSD17B10CYP1A2
SCHEMBL10129758 0.83 HPGD (0.41) HPGDMAPTTSHRRXRARXRB
SCHEMBL10112476 0.82 PTGER4 (0.44) HPGDKDM4EHSD17B10PTGER4ALDH1A1
SCHEMBL10112502 0.82 EDNRA (0.42) HPGDMAPTKDM4EHSD17B10TSPO
SCHEMBL8406163 0.82 L3MBTL1 (0.45) MAPTKDM4EHSD17B10PTGER4TSPO
SCHEMBL36208 0.82 KDM4E (0.47) HPGDMAPTKDM4EHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110980-B2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-07 US disclosed
EP-1918350-B1 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LAB (JP) 2010-08-11 EP disclosed
US-20100164376-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2010-07-01 US disclosed
US-7674914-B2 novel anthracene derivative represented by General Formula (1) is provided, which enables the production of a light-emitting element with high luminous efficiency and a long lifetime. A high-performance light-emitting device and electronic device in which the anthracene derivative light emitting diode SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-03-09 US disclosed
EP-1918350-A2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-05-07 EP disclosed
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative AMY1A, CYP1A1, CRY1 HPGD 372/4885MAPT 4092/4885TSHR 4186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.